Clinical Trial Update: Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating ABP 798 versus rituximab in moderate to severe rheumatoid arthritis has completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ABP 798 (ABP 798)
• Rituximab (rituximab)

Snippet

Sponsor: Amgen | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2019-10-23